Moreover, plasma p-tau217 is strongly associated with measures of Aβ pathology and its levels change before tau-PET abnormalities are detectable in AD progression15–17, making it a feasible candidate to implement as a routine clinical chemistry test to screen for Aβ positivity in memory clinics. This evidence concerns the gene MAPT and Alzheimer disease.